A detailed history of Black Rock Inc. transactions in Cerus Corp stock. As of the latest transaction made, Black Rock Inc. holds 13,636,954 shares of CERS stock, worth $24.4 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,636,954
Previous 13,728,396 0.67%
Holding current value
$24.4 Million
Previous $29.7 Million 13.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.66 - $2.42 $151,793 - $221,289
-91,442 Reduced 0.67%
13,636,954 $25.8 Million
Q4 2023

Feb 13, 2024

SELL
$1.25 - $2.35 $246,616 - $463,638
-197,293 Reduced 1.42%
13,728,396 $29.7 Million
Q3 2023

Nov 13, 2023

SELL
$1.5 - $3.07 $127,584 - $261,121
-85,056 Reduced 0.61%
13,925,689 $22.6 Million
Q2 2023

Aug 11, 2023

BUY
$1.79 - $2.9 $1.8 Million - $2.91 Million
1,005,033 Added 7.73%
14,010,745 $34.5 Million
Q1 2023

May 12, 2023

BUY
$2.65 - $3.81 $1.09 Million - $1.57 Million
411,658 Added 3.27%
13,005,712 $38.6 Million
Q4 2022

Feb 13, 2023

BUY
$3.38 - $4.22 $1.26 Million - $1.58 Million
373,936 Added 3.06%
12,594,054 $46 Million
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.83 $137,302 - $233,374
40,030 Added 0.33%
12,220,118 $44 Million
Q2 2022

Aug 12, 2022

BUY
$4.41 - $5.69 $73,161 - $94,397
16,590 Added 0.14%
12,180,088 $64.4 Million
Q1 2022

May 12, 2022

SELL
$4.81 - $6.99 $209,494 - $304,442
-43,554 Reduced 0.36%
12,163,498 $66.8 Million
Q4 2021

Feb 10, 2022

SELL
$5.97 - $7.93 $7.39 Million - $9.81 Million
-1,237,035 Reduced 9.2%
12,207,052 $83.1 Million
Q3 2021

Nov 09, 2021

BUY
$4.79 - $6.68 $43,694 - $60,934
9,122 Added 0.07%
13,444,087 $81.9 Million
Q2 2021

Aug 11, 2021

BUY
$5.35 - $6.35 $71.9 Million - $85.3 Million
13,434,965 New
13,434,965 $79.4 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $317M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.